Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
88.19
+0.96 (+1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
August 22, 2024
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...
Via
Benzinga
Exposures
COVID-19
Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Unveiling 12 Analyst Insights On BioNTech
August 19, 2024
Via
Benzinga
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
August 19, 2024
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
Via
Benzinga
Topics
ETFs
Exposures
COVID-19
Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Via
MarketBeat
Exposures
COVID-19
Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
August 19, 2024
FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety...
Via
Benzinga
Exposures
Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
August 19, 2024
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19.
Via
The Motley Fool
Navigating 12 Analyst Ratings For BioNTech
August 01, 2024
Via
Benzinga
Why Pfizer Stock Slumped on Friday
August 16, 2024
Investors were cautiously pessimistic about the latest news coming out of the company's lab.
Via
The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
August 16, 2024
The company is now considering whether it needs to change up the vaccine to pass muster.
Via
Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
August 16, 2024
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve...
Via
Benzinga
Exposures
COVID-19
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
BioNTech SE
Via
GlobeNewswire
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
August 13, 2024
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among...
Via
Benzinga
Exposures
COVID-19
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
August 13, 2024
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to...
Via
Benzinga
Exposures
COVID-19
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Via
MarketBeat
Exposures
COVID-19
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.
Via
InvestorPlace
Exposures
Product Safety
This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
August 07, 2024
Via
Benzinga
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
August 05, 2024
BNTX earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday?
August 05, 2024
Global markets are experiencing intense volatility, and while it seemed like a Black Monday for Wall Street was inevitable following a 13% overnight tumble of Japan’s Nikkei 225, stock indices are...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Moderna sustained a rare downgrade on Monday following its guidance cut for the year.
Via
Investor's Business Daily
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024
August 05, 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
August 05, 2024
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...
Via
Benzinga
Exposures
COVID-19
Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears
August 05, 2024
The stock market is on track to gap-open sharply lower on Monday as negative sentiment seen in the final two sessions of last week has carried over into the new week. The index futures were all sharply...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
August 05, 2024
From
BioNTech SE
Via
GlobeNewswire
What's Going On With BioNTech (BNTX) Shares?
August 01, 2024
BioNTech shares are trading lower by 5.3% during Thursday's session. Vaccine stocks are down after Moderna cut its 2024 outlook due to weak EU sales and increased U.S. competition.
Via
Benzinga
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
August 01, 2024
Moderna delivered nearly double the sales analysts expected in the second quarter.
Via
Investor's Business Daily
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
July 30, 2024
From
BioNTech SE
Via
GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.